Review



l9 heavy and light chain sequences  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation l9 heavy and light chain sequences
    L9 Heavy And Light Chain Sequences, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/l9 heavy and light chain sequences/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    l9 heavy and light chain sequences - by Bioz Stars, 2026-05
    90/100 stars

    Images



    Similar Products

    l9 heavy and light chain sequences  (GenScript corporation)
    90
    GenScript corporation l9 heavy and light chain sequences
    L9 Heavy And Light Chain Sequences, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/l9 heavy and light chain sequences/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    l9 heavy and light chain sequences - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    l9 lineage pfcsp immunoglobulin heavy and light chain variable region sequences  (GenScript corporation)
    90
    GenScript corporation l9 lineage pfcsp immunoglobulin heavy and light chain variable region sequences
    (A) Ig heavy and light chain pairings matched to create normal mAbs <t>(L9,</t> F10, L9MRCA) and chimeric mAbs (L9HF10κ, F10HL9κ, D2HL9κ, D2HF10κ) used in this study. Each heavy and light chain’s divergence from germline is depicted. (B) Binding of various concentrations of indicated mAbs to rPfCSPFL (left), peptide 22 (NANPNVDPNANPNVD, middle), and (NANP)9 (right) measured by ELISA; optical density at 450 nm (OD450) is plotted. The NANP-preferring <t>PfCSP</t> mAb 317 and the anti-gp120 mAb VRC01 were included as positive and negative controls, respectively. (C) Binding response (nm) and apparent avidity (KDapp, nM) of indicated mAbs binding to peptide 22 determined through BLI. (D) Competition ELISA of indicated mAbs binding to rPfCSPFL and various concentrations of peptide 22 (rightmost bar) or variant peptides (other bars) where the indicated amino acid was mutated to alanine or serine. Area under the curve (AUC) is plotted. (E) SEC plots of indicated Fabs incubated with peptide 22 (Fabs alone, black peak; Fabs+pep22, blue peak). All data are representative of two independent experiments. See also Figure S2 and Table S1.
    L9 Lineage Pfcsp Immunoglobulin Heavy And Light Chain Variable Region Sequences, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/l9 lineage pfcsp immunoglobulin heavy and light chain variable region sequences/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    l9 lineage pfcsp immunoglobulin heavy and light chain variable region sequences - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Ig heavy and light chain pairings matched to create normal mAbs (L9, F10, L9MRCA) and chimeric mAbs (L9HF10κ, F10HL9κ, D2HL9κ, D2HF10κ) used in this study. Each heavy and light chain’s divergence from germline is depicted. (B) Binding of various concentrations of indicated mAbs to rPfCSPFL (left), peptide 22 (NANPNVDPNANPNVD, middle), and (NANP)9 (right) measured by ELISA; optical density at 450 nm (OD450) is plotted. The NANP-preferring PfCSP mAb 317 and the anti-gp120 mAb VRC01 were included as positive and negative controls, respectively. (C) Binding response (nm) and apparent avidity (KDapp, nM) of indicated mAbs binding to peptide 22 determined through BLI. (D) Competition ELISA of indicated mAbs binding to rPfCSPFL and various concentrations of peptide 22 (rightmost bar) or variant peptides (other bars) where the indicated amino acid was mutated to alanine or serine. Area under the curve (AUC) is plotted. (E) SEC plots of indicated Fabs incubated with peptide 22 (Fabs alone, black peak; Fabs+pep22, blue peak). All data are representative of two independent experiments. See also Figure S2 and Table S1.

    Journal: Cell reports

    Article Title: The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria

    doi: 10.1016/j.celrep.2022.110367

    Figure Lengend Snippet: (A) Ig heavy and light chain pairings matched to create normal mAbs (L9, F10, L9MRCA) and chimeric mAbs (L9HF10κ, F10HL9κ, D2HL9κ, D2HF10κ) used in this study. Each heavy and light chain’s divergence from germline is depicted. (B) Binding of various concentrations of indicated mAbs to rPfCSPFL (left), peptide 22 (NANPNVDPNANPNVD, middle), and (NANP)9 (right) measured by ELISA; optical density at 450 nm (OD450) is plotted. The NANP-preferring PfCSP mAb 317 and the anti-gp120 mAb VRC01 were included as positive and negative controls, respectively. (C) Binding response (nm) and apparent avidity (KDapp, nM) of indicated mAbs binding to peptide 22 determined through BLI. (D) Competition ELISA of indicated mAbs binding to rPfCSPFL and various concentrations of peptide 22 (rightmost bar) or variant peptides (other bars) where the indicated amino acid was mutated to alanine or serine. Area under the curve (AUC) is plotted. (E) SEC plots of indicated Fabs incubated with peptide 22 (Fabs alone, black peak; Fabs+pep22, blue peak). All data are representative of two independent experiments. See also Figure S2 and Table S1.

    Article Snippet: L9 lineage PfCSP immunoglobulin heavy and light chain variable region sequences , GenScript , GenBank Accession Numbers MZ686952 – MZ686956.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Variant Assay, Incubation

    (A) Left: binding of various concentrations of indicated mAbs to Pb-PfCSP-SPZ determined by flow cytometry; median fluorescence intensity (MFI) of mAb-bound SPZ is plotted. Mean and standard error of the mean (SEM) MFI values from four independent experiments are shown except for L9MRCA, which was from two experiments. Right: area under the curve (AUC) and SEM values calculated from the MFI plots. (B) Percentage (%) of SPZ undergoing the CSPR after incubation with 50 μg/mL of indicated mAb for 15 min. Bar graphs show the mean and SEM from six independent experiments. (C) Percentage of non-motile SPZ after incubation with 25 μg/mL of indicated mAb for 15 min. Bar graphs show the mean and SEM from two independent experiments. (B-C): P-values reflect comparisons between L9κ-containing mAbs and their F10κ-containing counterparts using Fisher’s exact test. (D) Reduction in parasite bioluminescence (total flux, photons/sec) in the livers of mice (n=15/group; data pooled from three independent experiments indicated by squares, circles, and triangles) mediated by 100 μg of indicated mAbs administered 2 hrs before IV challenge with 2,000 Pb-PfCSP-SPZ. P-values reflect comparisons between L9κ-containing mAbs and their F10κ-containing counterparts using the two-tailed Mann–Whitney test. (E) Survival curves of mice (n=7/group) challenged with five infected mosquito bites 24 hrs after passive transfer of 300 μg of indicated mAb.

    Journal: Cell reports

    Article Title: The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria

    doi: 10.1016/j.celrep.2022.110367

    Figure Lengend Snippet: (A) Left: binding of various concentrations of indicated mAbs to Pb-PfCSP-SPZ determined by flow cytometry; median fluorescence intensity (MFI) of mAb-bound SPZ is plotted. Mean and standard error of the mean (SEM) MFI values from four independent experiments are shown except for L9MRCA, which was from two experiments. Right: area under the curve (AUC) and SEM values calculated from the MFI plots. (B) Percentage (%) of SPZ undergoing the CSPR after incubation with 50 μg/mL of indicated mAb for 15 min. Bar graphs show the mean and SEM from six independent experiments. (C) Percentage of non-motile SPZ after incubation with 25 μg/mL of indicated mAb for 15 min. Bar graphs show the mean and SEM from two independent experiments. (B-C): P-values reflect comparisons between L9κ-containing mAbs and their F10κ-containing counterparts using Fisher’s exact test. (D) Reduction in parasite bioluminescence (total flux, photons/sec) in the livers of mice (n=15/group; data pooled from three independent experiments indicated by squares, circles, and triangles) mediated by 100 μg of indicated mAbs administered 2 hrs before IV challenge with 2,000 Pb-PfCSP-SPZ. P-values reflect comparisons between L9κ-containing mAbs and their F10κ-containing counterparts using the two-tailed Mann–Whitney test. (E) Survival curves of mice (n=7/group) challenged with five infected mosquito bites 24 hrs after passive transfer of 300 μg of indicated mAb.

    Article Snippet: L9 lineage PfCSP immunoglobulin heavy and light chain variable region sequences , GenScript , GenBank Accession Numbers MZ686952 – MZ686956.

    Techniques: Binding Assay, Flow Cytometry, Fluorescence, Incubation, Two Tailed Test, MANN-WHITNEY, Infection

    KEY RESOURCES TABLE

    Journal: Cell reports

    Article Title: The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria

    doi: 10.1016/j.celrep.2022.110367

    Figure Lengend Snippet: KEY RESOURCES TABLE

    Article Snippet: L9 lineage PfCSP immunoglobulin heavy and light chain variable region sequences , GenScript , GenBank Accession Numbers MZ686952 – MZ686956.

    Techniques: Virus, Recombinant, Construct, SYBR Green Assay, Staining, Expressing, Crystallization Assay, Luciferase, Amplification, Software, In Vivo Imaging, Fluorescence, Microscopy